01 July 1999
Comparison of different groups of cholesterol lowering drugs and total mortality: a meta-analysis
Adam SternoMed Sci Monit 1999; 5(4): SR786-793 :: ID: 504675
Abstract
Introduction: The aim of this study was to compare different groups of cholesterol lowering drugs. Material: Randomized trials were included if: (1) they lasted for 2 years or more, (2) the intention to treat total mortality data was obtainable, (3) at least one death had occurred, (4) one cholesterol lowering drug (fibrate, nicotinic acid and its derivate acipimox, resin, statin or probucol) was used, (5) they were published before the end of 1997. Computerized database (MEDLINE), references from former meta-analyses, overviews and already located trials were the source of data. Method: Meta-analysis. We used the conventional pooled odds ratio (OR) method. OR was calculated for each drug and for each group of drugs. Results: 26 trials were included. Out of all drug groups the total mortality only decreased amongst statins OR=0.76 (95% CI 0.68-0.86). Fibrates OR=1.08 (95% CI 0.97Ð1.21), nicotinic acid together with acipimox OR=0.94 (95% CI 0.81-1.09), resins OR=0.86 (95% CI 0.66-1.11) had no effect on the total mortality. We found no trials with probucol. Similar results were obtained following an additional analysis using the same methods and involving trials with the percentage of patients with unknown vital conditions (5% and no cholestyramine. These conclusions could only be valid in the case of patients with hypercholesterolemia and mixed hyperlipidemia with only moderately elevated triglyceride levels. Randomized, long term trials did not involve patients with hypertriglyceridemia and mixed hyperlipidemia with considerably elevated triglyceride levels. Conclusions: There exists a difference in the total mortality between different groups of cholesterol lowering drugs. Only statins lowered the total mortality.
Keywords: Mortality, cholesterol lowering drugs, cholesterol level
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952